AstraZeneca: developing self-amplifying RNA with VaxEquity
(CercleFinance.com) - AstraZeneca has reached an agreement to collaborate with VaxEquity for the discovery, development and commercialisation of the proprietary self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London.
The strategic, long-term research collaboration aims to optimise and validate VaxEquity's saRNA platform and apply it to advance novel therapeutic programmes.
AstraZeneca will support VaxEquity with research and development funding and should AstraZeneca advance any of the research programmes into its pipeline, VaxEquity could receive development, approval and sales-based milestones totalling up to $195 million and royalties in the mid-single digits per programme.
AstraZeneca has the option to collaborate with VaxEquity on up to 26 drug targets and will also make an investment in VaxEquity to further the development of the saRNA platform.
Copyright (c) 2021 CercleFinance.com. All rights reserved.